These findings signify the intriguing possibility that anti-TGF-β1 therapeutics could be used to target ovarian cancer cells and anti-TGF-β3 therapies could be used to inhibit CAFs in COL11A1-positive tumors (36). This evidence concerns the gene TGFB3 and ovarian cancer.